Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
Status:
Terminated
Trial end date:
2012-01-23
Target enrollment:
Participant gender:
Summary
This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with
relapsing forms of multiple sclerosis. The study will specifically investigate safety (vital
signs like heart rate, blood pressure, Magnetic Resonance Imaging (MRI), and other markers of
health from blood samples), tolerability (any side effects that occur, if any), and
pharmacokinetics (how the body processes the drug and how long the drug stays in the blood,
and in cerebro-spinal fluid). The study will also investigate if patients' own immune system
interacts with GSK1223249.